ANDA 74421, held by PLIVA. Cyclobenzaprine Hydrochloride.
As of Nov 21, 2026, ANDA 74421 (Cyclobenzaprine Hydrochloride), held by PLIVA, was first approved by FDA on Sep 29, 1995, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 29, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cyclobenzaprine Hydrochloride10MG · tablet;oral | Cyclobenzaprine Hydrochloride | Discontinued |
| Apr 11, 2013 | Supplement 33Labeling · Standard review | Approved | None posted |
| Apr 2, 2013 | Supplement 32Manufacturing | Approved | None posted |
| Mar 16, 2010 | Supplement 21Labeling | Approved | None posted |
| May 29, 2001 | Supplement 5Manufacturing | Approved | None posted |
| Mar 16, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Nov 20, 2000 | Supplement 3Manufacturing | Approved | None posted |
| Jul 7, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Jul 1, 1996 | Supplement 1Manufacturing | Approved | None posted |
| Sep 29, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters